Tukysa savings card: as little as $0 a month with commercial insurance

How to pay the least

Ask for the cash price

Tukysa

We didn’t find one.

Ask your pharmacy for Tukysa’s cash price, and one or two other pharmacies too.
Tukysa’s savings card works only with insurance from a job or one you bought.

Compare every option

Brand nameTukysa

Authorized generictucatinib

Regular generictucatinib

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldNone found

Same as Tukysa?

The original

–

Brand nameThe maker’s card

Pfizer Oncology Together Co-Pay Savings Program (Oral Products)

Savings card from Pfizer (Seagen)

No insuranceNeeds insuranceNo cash price listed.

Insurance · as little as $0 a month

The card takes up to $10,000 a year off your co-pay.

Or call 1-877-744-5675. See the offer on pfizeroncologytogether.com

In the maker’s words

“pay as little as $0 per month for TUKYSA and for capecitabine when taken in combination with TUKYSA.”

From the maker’s offer on pfizeroncologytogether.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Tukysa itself, from the same company, sold without the brand name, and usually for less. For now Tukysa is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

TUKYSA is a kinase inhibitor indicated:

in combination with trastuzumab and pertuzumab for the maintenance treatment of adult patients with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment.
in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.
in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Source: the FDA label for Tukysa (SEAGEN INC.), October 14, 2026. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to your pharmacy.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/tukysa/